Breastfeeding, Covid19, Vaccine Exposure Via Breast Milk
Conditions
Brief summary
This is a study prospective cohort study at an urban academic centre, with two parts: 1. Health outcomes, and maternally transferred antibodies, in babies born to mothers who had antenatal COVID-19 and convalesced before delivery, followed up until 12 months of age 2. Safety and protective properties of breast milk after lactating women are vaccinated against COVID-19
Detailed description
This proposal aims to provide a multi-faceted approach to study how immunity may be transferred - both transplacentally and through breastfeeding, from mother to child, in the context of COVID-19. We first recruit all babies delivered to mothers convalescent from antenatal COVID-19, to 1) follow up their growth and development, and 2) study the protective effects of antibodies transferred from mother to child transplacentally during pregnancy, as well as postnatally through breastfeeding. We compare these to a cohort of healthy controls whose mothers did not have COVID-19 during pregnancy. Next, we compare the protective effects of antibodies transferred during breastfeeding from mother to child after lactating mothers are vaccinated against COVID-19, to that of natural infection. We also study the safety of breastfeeding after vaccination by looking for vaccine components in the breast milk.
Interventions
BIOLOGICALCOVID-19 vaccine
Any COVID-19 vaccine
Sponsors
National University of Singapore
Agency for Science, Technology and Research
National University Hospital, Singapore
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
Lives in Singapore
Exclusion criteria
Prematurity Congenital abnormalities Primary immunodeficiencies Autoimmune disorders
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transplacentally transferred antibodies | From birth to 12 months of age | Binding and neutralising immunoglobulin G specific to SARS-CoV-2 spike and receptor-binding domain |
| Antibodies transferred through breast milk (convalescent mothers) | From birth to 6 months of age | Binding and neutralising immunoglobulin A specific to SARS-CoV-2 spike and receptor-binding domain |
| Antibodies transferred through breast milk (vaccinated mothers) | From just before vaccination, to 6 weeks after vaccination | Binding and neutralising immunoglobulin A specific to SARS-CoV-2 spike and receptor-binding domain |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| General health | From birth to 12 months of age | Growth and development of infants |
Countries
Singapore
Contacts
Primary ContactJia Ming Low, MBBS, MCI
Backup ContactYoujia Zhong, MBChB, MCI
Outcome results
None listed